The follow-up study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon.
The study will be conducted by Translational Drug Development (TD2) in the U.S. which was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2.
Just a few weeks ago the company announced that this new trial would begin shortly. It is critical to remember the numerous bashers that immediately jumped upon that release predicting it was all fluff and would never happen. A particular regular here (who loves bold and cap font with lots of red for affect) broke down every comment and assured us all that this would never happen.
Now we see that these tests are indeed underway. This is so important that I am nothing short of thrilled. As I have stated before, the success of PMCB is based in the many laboratories in which we are working. Success in these labs will lead to the break away that we are patiently awaiting. The break away that will be unstoppable.
We have another player here who likes to do a quarterly countdown and try to assert that our company has achieved nothing in the first quarter of 2015. Well lets add this to list of nothing that we are accomplishing.
Thanks again Bull - it is always good to hear from you.
Bull, am I seeing this right r missing something that it seems that the global view of this co. is focused on the T1D studies to date and I am wondering if that might not signify a much better stability to PMCB (due to the volume) than one might expect since the move upward seems to be based on news not speculation.
News 
Market Data 
Discover 
